Core Insights - Medpace's shares increased by 13% this week, reflecting strong growth in its latest quarter and an optimistic outlook from investors [1] - The clinical trial industry is recovering post-COVID-19, contributing to Medpace's financial performance [2][4] Financial Performance - Medpace reported a revenue growth of 24% year over year, reaching $660 million, with a net income of $111 million [2] - The company's backlog has reached $3 billion, indicating strong demand for its services [4] Book-to-Bill Ratio - Medpace's book-to-bill ratio was 1.2x in the third quarter, suggesting that new contract wins are outpacing existing orders fulfilled, which is a positive sign for future growth [3][4] Stock Performance - Medpace's stock has increased over 100% since the beginning of the year, with a current price-to-earnings (P/E) ratio of 44.5, up from 24 earlier this year [7][9] - The company has experienced a remarkable revenue increase of 1,000% since going public in 2016 [6]